4G Clinical Launches New RTSM Software
Prancer RTSM Software Poised to Bring Innovation, Speed and Simplicity to Complex Clinical Trials
WELLESLEY, MA - 4G Clinical today announced the launch of Prancer, its 4th generation Randomization and Trial Supply Management (RTSM) system, as the world's first 100% configurable and flexible system capable of addressing the increasing complexities of clinical trials. "The most critical aspects of large phase 2 and phase 3 clinical trials – patient randomization, drug dispensing and site resupply are inadequately supported in the pharmaceutical industry," said Ed Tourtellotte, Founder and Chief Technology Officer at 4G Clinical. "Prancer was developed by a world-class team of industry veterans focused on addressing these limitations and pain points in the planning and execution of clinical trials." Prancer is built on a modern technology stack, enabling high quality, high speed development, system deployment, monitoring and security. One of Prancer's key innovations is the use of advanced natural language processing (NLP). Combined with custom clinical trials intelligence, NLP technology enables Prancer to read and interpret written RTSM specifications, understand them, and build a deployable system automatically. Prancer's clinical supply forecasting capability also differentiates it from other RTSM systems. The system uses smart statistical models to remove the burden of managing hundreds of poorly understood algorithm control parameters to forecast supply. Prancer simplifies the supply manager's role in forecasting supply with the use of more intuitive interfaces to determine an optimal supply strategy. "The technical capabilities of Prancer, combined with the experience and depth of our team, positions us to truly effect the way clinical trials are executed," said 4G Clinical CEO Dave Kelleher. "This launch brings us one step closer to having a meaningful impact on the time it takes to complete critical clinical trials." 4G will be unveiling Prancer at CBI's annual Interactive Response Technologies in Clinical Trials (IRT) conference this week, October 25-26, 2016, at the Hilton Philadelphia at Penn's Landing, Philadelphia, PA.
About the e-Clinical Trials Marketplace
Total global bio/pharmaceutical R&D spending has been estimated at around $127 billion and growing, with late-stage Clinical R&D accounting for about 20% of that total cost. The overall clinical trials marketplace is also generally accepted to be stable or growing. ClinicalTrials.gov, which includes an estimated 75% of clinical trials globally, shows a steadily increasing number of new clinical trials registered year-over-year for the last two decades. In the past 10 years, there has been an average of nearly 17,000 new registered trials annually, with numbers in the last 5 years being consistently higher – between 20,000 and 24,000. Already in 2016, there are more than 20,000 new clinical trials registered.
About 4G Clinical
4G Clinical is a full service RTSM company focused on simplifying and accelerating the drug development process. The company was founded in October, 2015, to develop a service offering centered around a 4th generation Randomization and Trial Supply Management (RTSM) system, Prancer. Headquartered in the heart of the Boston biotech corridor, in Wellesley, MA, 4G Clinical has facilities and staff located in the U.S. and Europe, and offers global expertise and advisory services to pharmaceutical companies and contract research organizations. For more information, visit
www.4gclinical.com
.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
